Can a new drug cool down inflamed arteries and prevent heart attacks?
NCT ID NCT06263244
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether ziltivekimab, a drug that targets inflammation, can reduce swelling in the arteries of 40 people with coronary artery disease. Participants receive either the drug or a placebo, and researchers use advanced imaging and blood tests to measure changes. The goal is to see if this approach can lower inflammation, which is linked to heart attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ziltivekimab (a monoclonal antibody targeting IL-6)
What this could lead to
If it works, this could point toward a treatment that lowers inflammation in arteries, potentially reducing heart attack risk.
What could go wrong
This is a small, early-phase trial focused on imaging and lab markers, not clinical outcomes like heart attacks. The drug may not show clear benefits or could have side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, location AMC
RECRUITINGAmsterdam, 1105AZ, Netherlands